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Condensed abstract 
The association between angiotensin receptor blockers (ARBs) and inflammatory markers 
was assessed in a population-based prospective study conducted in Lausanne, Switzerland. 
Data from 933 (baseline, 2003-6) and 1120 (follow-up, 2009-12) participants on 
antihypertensive drugs was used. No differences were found between participants taking or 
not taking ARBs for C-reactive protein, interleukins 1β and 6 and tumor necrosis factor 
alpha. These findings were replicated in the follow-up study, and comparing participants 
who received ARBs during follow-up with participants on other antihypertensive drugs. We 
conclude that ARBs are not associated with reduced levels of inflammatory markers in the 
general population. 
Highlights 
• We assessed the association between ARBs and inflammatory markers 
• The associations were assessed cross-sectionally and prospectively  
• A population-based sample of patients treated for hypertension was used 
• no association was found between ARBs and inflammatory markers 
 
ABSTRACT 
Objective: angiotensin receptor blockers (ARBs) have been suggested to reduce 
inflammation in randomized controlled trials. We assessed the association between ARBs 
and inflammatory markers in a general population setting.  
Methods: population-based prospective study conducted in Lausanne, Switzerland. Baseline 
data from 933 participants on antihypertensive drugs (424 on ARBs) was collected in 2003-6. 
Follow-up data from 1120 participants (572 on ARBs) was collected in 2009-12. C-reactive 
protein (CRP), interleukins 1β (IL-1β) and 6 (IL-6) and tumor necrosis factor alpha (TNF-α) 
were assessed and categorized in quartiles. 
Results: At baseline, no differences were found between participants taking or not taking 
ARBs for all inflammatory markers studied, and this association persisted after multivariate 
adjustment: Odds ratios and (95% confidence interval) for being in the highest quartile of IL-
1β,  IL-6, TNF-α and CRP for participants on ARB compared to participants not on ARB; 1.23 
(0.89-1.70); 1.26 (0.93-1.70); 1.14 (0.85-1.53) and 1.27 (0.96-1.69), respectively (P>0.05). 
These findings were further replicated in the follow-up study: OR and (95% CI) of 1.10 (0.78-
1.55); 0.87 (0.64-1.19); 0.83 (0.61-1.14) and 0.91 (0.68-1.22) for IL-1β, IL-6, TNF-α and CRP, 
respectively (P>0.05). Finally, no effect of ARBs was found when comparing participants who 
received ARBs throughout the 5.5 years follow-up with participants on other 
antihypertensive drugs: OR and (95% CI) of 0.93 (0.61-1.42); 0.80 (0.54-1.17); 0.86 (0.59-
1.25) and 0.95 (0.67-1.35) for IL-1β, IL-6, TNF-α and CRP, respectively (P>0.05). 
Conclusion: ARBs are not associated with reduced levels of inflammatory markers in the 
general population. 




Several studies have suggested that angiotensin receptor blockers (ARB), a class of 
antihypertensive drugs, could exert an anti-inflammatory effect (for a review, see [1]). 
Several mechanisms have been proposed, such as reduction of mitochondrial reactive 
oxygen species [2], cytokine production [3, 4] or  inflammatory response of macrophages to 
lipopolysaccharide [5, 6] via the activation of the peroxisome proliferator-activated receptor-
gamma [7]. In humans, ARB have been shown to reduce fibrinogen [8], CRP [8, 9], 
interleukin-6 [10], TNF-α [11, 12] and vascular cell adhesion molecule-1 levels [12], although 
these effects have been challenged [13, 14]. Still, most human studies were conducted using 
a limited sample size or only diseased subjects [1], and it is unclear whether the anti-
inflammatory effects of ARBs observed in randomized controlled trials with a considerable 
selection procedure also apply to the general population. 
Thus, our study aimed to assess the impact of ARB on inflammatory markers in a 
general population setting. 
METHODS 
Participants 
The methodology of the CoLaus study has been described previously [15]. The study 
was approved by the Institutional Ethic's Committee of the University of Lausanne and all 
participants provided informed consent prior to being interviewed. Briefly, a simple random 
sample of the population aged between 35 and 75 years of the city of Lausanne 
(Switzerland) was drawn from the complete list of Lausanne’s inhabitants provided by the 
population register of the city and invited to participate. Inclusion criteria were 1) living in 
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Lausanne; 2) age between 35 and 75 years and 3) willingness to participate and to provide 
informed consent. Participation rate was 41% [15]. 
After a median follow-up time of 5.4 years (interquartile range: 5.3–5.6 years), 
participants were invited to attend a second examination, which included the same 
assessments as for baseline. 
Personal and clinical data 
All participants attended the outpatient clinic of the University Hospital of Lausanne 
in the morning after an overnight fast (minimum fasting time 8 hours). Data were collected 
by trained field interviewers in a single visit lasting about 60 min. The procedures were 
identical for the baseline and the follow-up surveys. 
Participants received a questionnaire to record information about their status and 
lifestyle factors. Marital status was defined as married, divorced, single and widowed. 
Educational level was stratified into low (primary), middle (apprenticeship, secondary 
school) and high (university). Smoking status was classified as never, current or former 
smoker. Physical activity was defined as the practice of leisure time physical activity at least 
twice per week. Alcohol consumption was assessed by asking the participant how many 
units of alcoholic beverages (i.e. cans of beer, glasses of wine) he/she had consumed during 
the previous week, and categorized as drinker/non drinker. Caucasian ethnicity was defined 
if the parents and grandparents of the participants were born in a selected list of countries 
(available from the investigators). 
Body weight and height were measured in light indoor clothes with shoes off. Body 
weight was measured in kilograms to the nearest 100g using a Seca® scale, which was 
calibrated regularly. Height was measured to the nearest 5 mm using a Seca® height gauge. 
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Body Mass Index (BMI) was calculated as weight (kg) divided by the square of the height (m). 
Overweight was defined as BMI ≥25 kg/m2 and <30 kg/m2, and obesity by a BMI ≥30 kg/m2. 
Diabetes was defined as a fasting plasma glucose ≥7 mmol/L or presence of 
antidiabetic drug treatment (oral or insulin). Information on the use of prescription and over 
the counter drugs was collected, together with their main indications. Collection was done 
by asking the participant to bring the drugs to the visit. 
As antihypertensive drug treatment might be prescribed differently according to the 
presence of other comorbidities or of renal disease, we calculated the Functional 
Comorbidity Index (FCI) [16] at baseline and estimated the glomerular filtration rate (eGFR) 
according to the Modification of Diet in Renal Disease (MDRD) equation [17] at baseline and 
follow-up for each participant. 
Antihypertensive drug treatment 
All antihypertensive drugs reported and brought by the participants were coded 
using the Anatomical Therapeutic Chemical classification system [18]. In both baseline and 
follow-up, antihypertensive drugs were classified into six different binary categories 
(yes/no): 1) Diuretics (isolated or associated with other drugs); 2) Calcium channel blockers 
(CCBs); 3) Beta-blockers (BBs); 4) Angiotensin-converting enzyme inhibitors (ACEIs); 5) 
Angiotensin receptor blockers (ARB) and 6) Other (reserpine). Combinations were split into 
the drug classes they contained; for example ATC code C08GA01, corresponding to 
nifedipine and diuretics, was split into “diuretics associated with other drugs” and “calcium 
channel blockers”. For statistical analysis, another two categories: were created ARBs 





For both the baseline and the follow-up surveys, most biological assays were 
performed by the CHUV Clinical Laboratory on fresh blood samples within 2 hours of blood 
collection. Glucose was measured by glucose dehydrogenase, with a maximum inter-batch 
coefficient of variation (CV) of 2.1% and a maximum intra-batch CV of 1.0%. High sensitive 
CRP was measured by immunoassay and latex HS, with a maximum inter-batch CV of 4.6% 
and a maximum intra-batch CV of 1.3%. Cytokines were measured using a multiplexed 
particle-based flow cytometric cytokine assay. Milliplex kits were purchased from Millipore 
(Zug, Switzerland). The procedures closely followed the manufacturer’s instructions. The 
analysis was conducted using a conventional flow cytometer (FC500 MPL, BeckmanCoulter, 
Nyon, Switzerland). Lower detection limits for IL-1β, IL-6 and TNF-α were 0.2 pg/ml. A good 
agreement between signal and cytokine was found within the assay range (R2≥0.99). Intra 
and inter-assay coefficients of variation were 15% and 16.7% for IL-1β, 16.9% and 16.1% for 
IL-6 and 12.5% and 13.5% for TNF-α, respectively. Repeated measurements were conducted 
in 80 subjects randomly drawn from the initial sample; Spearman rank correlations between 
duplicate measurements were 0.914, 0.961 and 0.891 for IL-1β, IL-6 and TNF-α (all p<0.001). 
Statistical analysis 
Participants were excluded from the analysis if they 1) presented an inflammatory 
status (defined by CRP values ≥20 mg/L) or 2) reported taking any type of anti-inflammatory 
drug or any type of systemic antibiotic. As the analysis was restricted to participants 
receiving antihypertensive drug treatment, all untreated participants (exclusion criterion 3) 
were also excluded. 
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Statistical analyses were performed using Stata version 13.0 for windows (Stata Corp, 
College Station, Texas, USA). Due to the skewed distribution of inflammatory markers, a 
categorization into quartiles was performed, including all values below the detection limit in 
the first quartile. Categorization was performed using data from the whole sample after 
excluding participants with exclusion criteria 1) and 2) This procedure was preferred to the 
log-transformation of the data, which in several cases did not lead to a normal-distributed 
variable and could not adequately handle results below the detection limit. Descriptive 
results were expressed as number of participants and (percentage) or as average ± standard 
deviation. Bivariate analyses were performed using chi-square test for qualitative variables 
and Student’s t-test or analysis of variance for quantitative variables.  
Multivariate analysis was performed by logistic regression on baseline data and using 
non-treated participants as reference. The results were expressed as Odds ratio (OR) and 
95% confidence interval (CI). Two models were applied: 1) assessing the likelihood of being 
in the topmost quartile relative to the other three quartiles and 2) assessing the likelihood of 
being in the topmost quartile relative to the lowest one. A second set of analysis was 
conducted using only participants treated for hypertension and comparing participants 
taking ARB to participants not taking ARB. The whole analytical procedure was replicated 
using data from the follow-up period. Due to the number of comparisons performed, 
statistical significance was assessed for p<0.001. 
RESULTS 
Characteristics of participants at baseline 
Of the 6733 participants at baseline, 933 (13.9%) were included. The reasons for 
exclusion are summarized in figure 1. Of the 933 participants retained, 424 (45.4%) were on 
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ARBs, but none of them had ARBs on monotherapy; their characteristics according to group 
are summarized in table 1. Participants on ARBs had a higher BMI, and were more frequently 
obese and less frequently widowed than participants not taking ARBs, while no differences 
were found for all other characteristics (table 1). 
Association of ARB treatment with inflammatory markers 
The distribution within the different quartiles of inflammatory markers according to 
antihypertensive drug treatment is summarized in table 2. No differences were found 
between participants taking or not taking ARBs for all inflammatory markers studied. 
Participants on ARBs had a borderline (p<0.07) higher likelihood of being in the highest 
quartile of CRP than participants not taking ARBs (table 2). 
Multivariate analysis was conducted adjusting for gender, age, marital status, 
physical activity, education categories, alcohol drinking (yes/no), smoking categories, body 
mass index categories and diabetes (yes/no). The results are summarized in table 3. No 
differences were found between participants taking or not taking ARBs. A further analysis 
assessing the individual effect of each type of antihypertensive drug using diuretics as 
reference showed no specific effect of ARB on inflammatory markers, although a borderline 
higher likelihood of being the highest quartile of TNF-α was found for ARB (table 3). 
Replication in the follow-up survey 
Of the 5064 participants (75.2% of baseline) who completed the follow-up, 1120 
(22%) were treated for hypertension and thus included in the analysis (supplementary figure 
1). Replication of the analysis confirmed the lack of specific effect of ARB on all four 
inflammatory markers (supplementary tables 1 and 2). 
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Of the 1093 participants treated for hypertension and who completed the follow-up, 
572 (52%) had no ARB at baseline and follow-up, 268 (25%) had no ARB at baseline but had 
ARB prescribed during follow-up, and 253 (23%) had ARB at baseline and follow-up. 
Multivariate analysis comparing the groups with previous or newly introduced ARBs relative 
to participants who never had ARB showed no specific effect of ARB on inflammatory 
markers (table 4). 
DISCUSSION 
To our knowledge, this is one of the first studies to assess the anti-inflammatory 
effect of ARBs in a general population setting. Our results do not confirm a specific anti-
inflammatory effect of ARB relative to the other antihypertensive drugs. 
Angiotensin II type 1 receptor activation has been shown to increase TNF-α 
production in rats [19], prompting the hypothesis that ARBs could have anti-inflammatory 
properties. Indeed, several mechanisms for the anti-inflammatory effect of ARBs have been 
suggested (for a review, see [1]) and a number of randomized controlled trials (RCTs) have 
shown that ARBs decrease inflammatory markers such as CRP, TNF-α or IL-6, although this 
statement has been challenged. Indeed, out of the 27 studies assessing the effect of ARB on 
CRP levels reviewed in [1], 12 (44%) reported nonsignificant changes, the effect ranging 
between a 44% decrease [20] and a 90% increase [21] in CRP levels. Similarly, the effect of 
ARBs on TNF-α and IL-6 ranged between -39% and +6.8% and between -39% and -4%, 
respectively [1].  
Possible explanations for the discrepancy between the results of RCTs and our study 
are that most RCTs used log-transformed data, while in this study a more conservative 
approach was preferred. Still, multivariate analysis of the effect of ARBs on inflammatory 
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markers using log-transformed data failed to show any significant difference (p-values of 
0.08, 0.11, 0.22 and 0.12 for IL-1β, IL-6, TNF-α and CRP, respectively). Hence, it is unlikely 
that the differences observed between our study and previous RCTs are due to differences in 
statistical methodology. Similarly, the mean age and male / female ratio of our study did not 
overtly differ from those of most RCTs (see supplementary table 3), so it is also unlikely that 
the differences observed between our study and previous RCTs are due to gender or age. 
The most likely explanation for the discrepancy between the results of most RCTs and 
our study might be the time period. Indeed, most RCTs were conducted for a limited period 
of time: only one [22] took longer than 6 months. ARBs block angiotensin II receptors, 
leading to an increase in renin levels via a feedback loop [23]. The resulting increased levels 
of renin and prorenin would increase the activity of (pro)renin receptors (P)RR [23], leading 
to an increased inflammatory cytokine production by the kidney [24]. The (P)RR could 
enhance the production of these inflammatory cytokines through direct stimulation of 
ERK1/2-NF-kappaB signaling cascade [25]. Interestingly, (P)RR blockers have been suggested 
to reduce sepsis-induced systemic inflammatory response in a rat model [26]. Thus, the 
initial decrease in inflammatory markers due to ARBs could be offset in the long run by an 
increased (P)RR-mediated cytokine production, thus explaining the lack of anti-inflammatory 
effect of ARBs observed in our study and also in the longest RCT [22]. Figure 2 summarizes 
the hypothesis explaining the lack of anti-inflammatory effect of ARBs in the long term. This 
mechanism could also explain the neutralization of the anti-inflammatory effect of ARBs by 
hydrochlorothiazide in the Val-MARC study [27], as hydrochlorothiazide has been shown to 
increase renin levels [28].  
Strengths and limitations  
10 
 
This study relied on a large, population-based sample of participants treated for 
hypertension; it thus reflects the expected, “real-life” effect of ARBs on inflammatory 
markers rather than the effect observed in a carefully selected group of patients from a RCT. 
The study was also based in sample considerably larger than most RCTs (supplementary 
table 3), thus enabling the detection of relatively small effect sizes. 
This study has several limitations worth acknowledging. First, no data was available 
regarding compliance, dosage or length of treatment with ARBs. Hence, it is possible that the 
putative anti-inflammatory effect of ARBs might have been lessened by noncompliers, 
participants on low dosage or on ARBs for a short period of time. Still, analysis of 
participants who received ARBs during 5.5 years follow-up and of participants newly 
prescribed with ARBs during follow-up did not show any significant effect relative to 
participants who received another class of antihypertensive drug. Overall, our results do not 
support a specific anti-inflammatory effect of ARBs or, if such an effect is present, its 
magnitude is too small to be detected using the current sample size. Second, it is possible 
that participants who were prescribed ARBs differed from participants not prescribed ARBs 
by other characteristics than those used for adjustment. Hence, we cannot completely rule 
out that the absence of anti-inflammatory effect of ARBs cannot be explained by 
unaccounted confounders. Third, it is possible that the other antihypertensive drugs also 
exert an anti-inflammatory effect, although most RCTs published failed to show such an 
effect [14, 29, 30]. As there were no participants on ARB monotherapy, the specific effect of 
ARB devoid of possible confounding by other antihypertensive drugs could not be assessed.  
Thus, any anti-inflammatory effect detected would be questionable, as it could not be solely 
attributed to ARBs beyond doubt. Fourth, it is possible that ARBs might exert an anti-
inflammatory effect at the local level, which could not be assessed by the circulating 
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inflammatory biomarkers used in this study. Fifth, no information was collected regarding 
dosage and duration of antihypertensive treatment; thus, no dose-dependent effect could 
be assessed and any minor effect on inflammatory markers might just not be recognizable in 
this data set. Finally, the CoLaus study recruited mainly participants of Caucasian origin (93% 
of the participants in this study), and it is currently unknown if our results also apply to other 
ethnicities. It would be of interest that this analysis be replicated in other studies conducted 
in other ethnicities to confirm or infirm our findings. 
CONCLUSION 
In a population-based setting, angiotensin receptor blockers are not associated with 
decreased levels of inflammatory markers. 
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Table 1: characteristics at baseline of participants according to treatment category 
 ARB No ARB p-value 
Sample size 424 509  
Women (%) 187 (44.1) 226 (44.4) 0.93 
Age (years) 59.7 ± 9.1 60.9 ± 9.3 0.07 
Marital status (%)   0.03 
Married 260 (61.3) 302 (59.3)  
Divorced 87 (20.5) 96 (18.9)  
Single 55 (13.0) 58 (11.4)  
Widowed 22 (5.2) 53 (10.4)  
Physical activity (%) 212 (50.0) 248 (48.7) 0.70 
Education (%)   0.56 
High 57 (13.5) 61 (12.1)  
Middle 85 (20.1) 115 (22.6)  
Low 282 (66.5) 332 (65.4)  
Alcohol drinker (%) 305 (71.9) 366 (71.9) 0.99 
Smoking status (%)   0.89 
Never 170 (40.1) 197 (38.8)  
Former 169 (39.9) 210 (41.3)  
Current 85 (20.0) 101 (19.9)  
BMI (kg/m2) 28.9 ± 5.0 27.7 ± 4.4 <0.001 
BMI categories (%)   0.005 
Normal 90 (21.2) 142 (27.9)  
Overweight 182 (42.9) 231 (45.4)  
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Obese 152 (35.9) 136 (26.7)  
Caucasian origin 397 (93.6) 474 (93.1) 0.76 
Diabetes (%) 84 (19.8) 90 (17.7) 0.41 
FCI 1.64 ± 1.38 1.52 ± 1.31 0.18 
SBP (mm Hg) 141 ± 19 139 ± 17 0.17 
DBP (mm Hg) 84 ± 11 83 ± 11 0.05 
eGFR (mL / min / 1.73m2) 73.8 ± 15.4 76.1 ± 19.2 0.05 
 
Results are expressed as mean ± standard deviation or as number of participants (percentage). ARB, 
angiotension-receptor blockers; BMI, body mass index; FCI, functional comorbidity index; SBP, 
systolic blood pressure; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate. 




Table 2: distribution within cytokine quartiles of participants treated with angiotensin receptor 
blockers and treated with other antihypertensive drugs, CoLaus baseline data. 
Quartile First Second Third Fourth p-value 
Interleukin 1β      
ARB 59 (25.3) 58 (24.9) 59 (25.3) 57 (24.5) 0.59 
No ARB 83 (30.7) 55 (20.4) 68 (25.2) 64 (23.7)  
Interleukin 6 (%)      
ARB 72 (18.5) 84 (21.5) 118 (30.3) 116 (29.7) 0.32 
No ARB 80 (17.8) 114 (25.3) 143 (31.8) 113 (25.1)  
Tumor necrosis factor α      
ARB 74 (18.3) 90 (22.2) 110 (27.2) 131 (32.4) 0.68 
No ARB 99 (20.8) 106 (22.2) 130 (27.3) 142 (29.8)  
C-reactive protein      
ARB 61 (14.4) 71 (16.8) 122 (28.8) 170 (40.1) 0.07 
No ARB 79 (15.5) 111 (21.8) 154 (30.3) 165 (32.4)  
 
Results are expressed as number of subjects and (percentage). ARB, angiotension-receptor blockers. 
Statistical analysis by chi-square. 
20 
 
Table 3: multivariate analysis of the effect of angiotensin receptor blockers on inflammatory markers, CoLaus baseline data. 
 Interleukin-1β Interleukin-6 TNF-α CRP 
Last vs. all other quartiles     
Model 1     
No angiotensin receptor blockers 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Angiotensin receptor blockers 1.26 (0.91 - 1.75) 1.27 (0.94 - 1.71) 1.14 (0.85 - 1.53) 1.26 (0.95 - 1.68) 
Model 2     
Diuretics 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Beta-blockers 1.08 (0.75 - 1.57) 1.12 (0.8 - 1.57) 1.04 (0.75 - 1.44) 1.16 (0.84 - 1.60) 
Calcium channel blockers 0.87 (0.57 - 1.34) 1.19 (0.82 - 1.72) 1.19 (0.83 - 1.71) 1.57 (1.11 - 2.23) * 
ACEIs 1.27 (0.86 - 1.87) 0.83 (0.58 - 1.20) 1.18 (0.83 - 1.67) 0.98 (0.69 - 1.37) 
Angiotensin receptor blockers 1.41 (0.96 - 2.07) 1.23 (0.86 - 1.75) 1.24 (0.88 - 1.74) 1.34 (0.96 - 1.87) 
Last vs. first quartile     
Model 1     
No angiotensin receptor blockers 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Angiotensin receptor blockers 1.24 (0.87 - 1.79) 1.34 (0.86 - 2.09) 1.20 (0.81 - 1.79) 1.24 (0.79 - 1.94) 
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Model 2     
Diuretics 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Beta-blockers 1.15 (0.77 - 1.74) 1.46 (0.87 - 2.43) 1.26 (0.79 - 2.01) 1.53 (0.9 - 2.59) 
Calcium channel blockers 0.96 (0.60 - 1.55) 1.17 (0.67 - 2.03) 1.40 (0.83 - 2.34) 2.07 (1.12 - 3.82) * 
ACEIs 1.21 (0.79 - 1.85) 1.03 (0.60 - 1.76) 1.54 (0.94 - 2.52) 0.98 (0.56 - 1.70) 
Angiotensin receptor blockers 1.39 (0.91 - 2.12) 1.51 (0.89 - 2.56) 1.53 (0.95 - 2.46) 1.39 (0.81 - 2.38) 
 
Results are expressed as odds-ratio (95% confidence interval) of being in the highest quartile. TNF-α, tumor necrosis factor α; CRP, C-reactive protein; ACEI; 
angiotensin-converting enzyme inhibitor. Statistical analysis by logistic regression adjusting for gender, age, marital status, physical activity, education 
categories, alcohol drinking (yes/no), smoking categories, body mass index categories, diabetes (yes/no), functional comorbidity index and estimated 




Table 4: multivariate analysis of the effect of changing antihypertensive treatment on inflammatory markers. 
 Interleukin-1β Interleukin-6 TNF-α CRP 
Last vs. all other quartiles     
No ARB at baseline and follow-up 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
No ARB at baseline, ARB at follow-up 1.13 (0.76 - 1.67) 0.94 (0.65 - 1.35) 0.70 (0.48 - 1.02) 0.92 (0.64 - 1.30) 
ARB at baseline and follow-up 0.91 (0.59 - 1.39) 0.78 (0.53 - 1.15) 0.82 (0.56 - 1.19) 0.93 (0.65 - 1.32) 
Last vs. first quartile     
No ARB at baseline and follow-up 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
No ARB at baseline, ARB at follow-up 1.60 (0.96 - 2.67) 1.13 (0.69 - 1.86) 0.81 (0.49 - 1.34) 1.05 (0.63 - 1.73) 
ARB at baseline and follow-up 0.91 (0.55 - 1.50) 0.79 (0.48 - 1.31) 0.79 (0.48 - 1.29) 0.91 (0.54 - 1.52) 
 
Data for all participants who completed the follow-up and who were retained for analysis. Results are expressed as odds-ratio (95% confidence interval) of 
being in the highest quartile. TNF-α, tumor necrosis factor α; CRP, C-reactive protein; ARB, angiotensin-receptor blockers.  Statistical analysis by logistic 
regression adjusting for gender, age, marital status, physical activity, education categories, alcohol drinking (yes/no), smoking categories, body mass index 
categories, diabetes (yes/no) and estimated glomerular filtration rate. 
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Figure 1: flowchart of the participant’s selection, baseline survey. 
Figure 2: hypothetical schema of the lack of anti-inflammatory effect of angiotensin receptor 
blockers. 
Supplementary figure 1: flowchart of the participant’s selection, follow-up survey. 
SUPPLEMENTAL MATERIAL 
Supplemental table 1:  distribution within cytokine quartiles of participants treated with angiotensin 
receptor blockers and with other antihypertensive drugs, CoLaus follow-up data. 
Quartile First Second Third Fourth p-value 
Interleukin 1β 
ARB 132 (25.3) 139 (26.7) 137 (26.3) 113 (21.7) 0.35 
No ARB 156 (30.2) 126 (24.3) 124 (24.0) 111 (21.5) 
Interleukin 6 
ARB 102 (19.5) 126 (24.1) 161 (30.9) 133 (25.5) 0.44 
No ARB 114 (22.0) 125 (24.1) 138 (26.5) 142 (27.4) 
Tumor necrosis factor α 
ARB 103 (19.7) 124 (23.8) 158 (30.3) 137 (26.2) 0.31 
No ARB 113 (21.8) 105 (20.2) 146 (28.1) 155 (29.9) 
C-reactive protein 
ARB 100 (17.9) 112 (20.0) 147 (26.3) 200 (35.8) 0.90 
No ARB 110 (19.6) 111 (19.8) 146 (26.0) 194 (34.6) 
Results are expressed as number of subjects and (percentage). ARB, angiotensin-receptor blockers. 
Statistical analysis by chi-square. 
Supplemental table 2: multivariate analysis of the effect of angiotensin receptor blockers on inflammatory markers, CoLaus follow-up data. 
 Interleukin-1β Interleukin-6 TNF-α CRP 
Last vs. all other quartiles     
Model 1     
No angiotensin receptor blockers 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Angiotensin receptor blockers 1.08 (0.77 - 1.53) 0.86 (0.63 - 1.17) 0.80 (0.59 - 1.10) 0.90 (0.67 - 1.20) 
Model 2     
Diuretics 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Beta-blockers 0.86 (0.56 - 1.31) 0.80 (0.55 - 1.17) 0.97 (0.66 - 1.40) 0.89 (0.62 - 1.26) 
Calcium channel blockers 0.95 (0.59 - 1.51) 0.68 (0.44 - 1.06) 1.32 (0.88 - 1.98) 1.11 (0.76 - 1.63) 
ACEIs 0.83 (0.49 - 1.39) 0.93 (0.58 - 1.47) 1.15 (0.73 - 1.83) 0.89 (0.58 - 1.37) 
Angiotensin receptor blockers 0.93 (0.57 - 1.51) 0.74 (0.48 - 1.16) 0.87 (0.56 - 1.35) 0.81 (0.54 - 1.23) 
Last vs. first quartile     
Model 1     
No angiotensin receptor blockers 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Angiotensin receptor blockers 1.29 (0.85 - 1.96) 0.94 (0.62 - 1.42) 0.84 (0.56 - 1.27) 0.95 (0.62 - 1.46) 
Model 2     
Diuretics 1 (ref.) 1 (ref.) 1 (ref.) 1 (ref.) 
Beta-blockers 0.84 (0.50 - 1.43) 0.82 (0.49 - 1.37) 0.98 (0.60 - 1.57) 0.95 (0.56 - 1.60) 
Calcium channel blockers 1.15 (0.64 - 2.08) 0.68 (0.38 - 1.23) 1.24 (0.72 - 2.14) 1.12 (0.63 - 1.98) 
ACEIs 0.97 (0.52 - 1.82) 0.85 (0.46 - 1.59) 1.04 (0.58 - 1.87) 0.72 (0.39 - 1.34) 
Angiotensin receptor blockers 1.19 (0.65 - 2.19) 0.79 (0.43 - 1.45) 0.87 (0.49 - 1.55) 0.79 (0.43 - 1.46) 
 
Results are expressed as odds-ratio (95% confidence interval) of being in the highest quartile. ACEI, angiotensin-converting enzyme inhibitor; TNF-α, tumor 
necrosis factor α; CRP, C-reactive protein. Statistical analysis by logistic regression adjusting for gender, age, marital status, physical activity, education 
categories, alcohol drinking (yes/no), smoking categories, body mass index categories, diabetes (yes/no) and estimated glomerular filtration rate.  
Supplemental table 3: comparison of the characteristics of the CoLaus sample with those from randomized controlled trials exploring the effect of 
angiotensin receptor blockers relative to other antihypertensive treatment on inflammatory markers 
Author (ref) Year 
Number of patients 
under ARB / total 
Mean age ± SD 
(ARB group) 
Male / Female ratio 
(ARB group) 
Duration of treatment 
Jilma 1 2002 15 / 32 59 ± 13 19 / 13 8 weeks 
Rahman 2 2002 19 / 38 43 ± 8.1 11 / 8 4 weeks 
Koh 3 2003 NR /  45 50 ± 2 33 / 12 2 months 
Fliser 4 2004 100 / 199 58 ± 9.8 47 / 53 12 weeks 
Koh 5 2004 NR /  47 57 ± 2 20 / 27 2 months 
Sardo 6 2004 20 / 40 49 ± 7.2 12 / 8 4 weeks 
Schieffer 7 2004 21 / 48 56 ± 8 16 / 5 3 months 
Manabe 8 2005 29 / 45 59 ± 14 16 / 13 3 months 
Rosei 9 2005 61 / 118 59 ± 7 41 / 20 24 weeks 
Schram 10 2005 24 / 70 60 ± 7 13 / 11 12 months 
Link 11 2006 21 / 42 58 ± 11.6 17 / 4 12 weeks 
Nagel 12 2006 20 / 20 36.8 ± 11.2 NR 12 weeks 
Nomura 13 2006 53 / 73 61 ± 7 9 / 16 8 weeks 
Ogawa 14 2006 33 / 66 58.7 ± 1.6 16 / 17 8 weeks 
Rajagopalan 15 2007 137 / 404 62.9 ± 8.1 71 / 66 12 weeks 
Ogawa 16 2009 13 / 13 NR 7 / 6 16 weeks 
All studies * 2002-9 666 / 1208 56.8 ± 8.7 348 / 279  
Current study 2006 424 / 509 60.3 ± 9.2 237 / 187  
 
NR; not reported; *, using available data 
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